Patients beware: The results of drug studies are heavily influenced by who footed the bill. And the industry probably won't change as long as there are researchers who need funding. Janet Babin reports.
Congress holds a hearing today on the safety of diabetes drug Avandia. GlaxoSmithKline is mounting an aggressive defense for its No. 2 seller. With sales already plummeting, there's a lot of cash on the line. Helen Palmer reports
The diabetes drug Avandia has been linked by a study to heart attacks and deaths. Commentator Dr. Stefan Kertesz says, in addition to the drug itself, the system that led to it being so heavily prescribed should be examined.
Amid scandal over tainted toothpaste coming out of the country, China held a press conference today to answer questions and stress that it's not as big of a deal as some countries are making it out to be, says Daniel Schearf.
Pfizer, the world's biggest drug maker is facing criminal charges in Nigeria related to a 1996 clinical trial. The company's accused in the deaths of children who received an unapproved antibiotic. Jeff Tyler reports.
As Americans get bigger, so does the weight-loss business. The diet industry is now a multibillion-dollar enterprise, one whose existence depends on our failures. Helen Palmer reports.
Soft drink and snack giant PepsiCo has brought one of the junk food industry's most outspoken critics on board to look out for consumer wellbeing. An unlikely match, but probably not a case of "healthwashing" says Stephen Beard.
Funny what labor and management are capable of when both sides are afraid of losing big. Detroit's Big Three automakers and the United Auto Workers may have actually found a win-win solution to fast-rising health care costs. Steve Tripoli has details.
The Democratic presidential candidates are rolling out their proposals for health care. We talked with economics professor Uwe Reinhardt about which ones might have a chance of becoming reality.
